These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 6254416)
1. Malignant glucagonoma syndrome: response to chemotherapy. Marynick SP; Fagadau WR; Duncan LA Ann Intern Med; 1980 Sep; 93(3):453-4. PubMed ID: 6254416 [TBL] [Abstract][Full Text] [Related]
2. Dimethyltriazenoimidazole carboxamide therapy of islet cell carcinoma of the pancreas. Awrich AE; Peetz M; Fletcher WS J Surg Oncol; 1981; 17(4):321-6. PubMed ID: 6267376 [TBL] [Abstract][Full Text] [Related]
3. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome. Altimari AF; Bhoopalam N; O'Dorsio T; Lange CL; Sandberg L; Prinz RA Surgery; 1986 Dec; 100(6):989-96. PubMed ID: 2878500 [TBL] [Abstract][Full Text] [Related]
4. Unsuccessful DTIC treatment of a patient with glucagonoma syndrome. Hallengren B; Dymling JF; Manhem P; Tennvall L; Tibblin S Acta Med Scand; 1983; 213(4):317-8. PubMed ID: 6310975 [TBL] [Abstract][Full Text] [Related]
5. A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome. Fujita J; Seino Y; Ishida H; Taminato T; Matsukura S; Horio T; Imamura S; Naito A; Tobe T; Takahashi K Cancer; 1986 Feb; 57(4):860-5. PubMed ID: 2867823 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of glucagonoma-related necrolytic migratory erythema with dacarbazine. van der Loos TL; Lambrecht ER; Lambers JC J Am Acad Dermatol; 1987 Feb; 16(2 Pt 2):468-72. PubMed ID: 3029193 [TBL] [Abstract][Full Text] [Related]
7. [Metastatic glucagonoma. Complete remission by dacarbazine (5 years' recession)]. Jeanmougin M; Civatte J; Bonvalet D; Passa P; Verola O; Zylberait D Ann Dermatol Venereol; 1988; 115(8):833-8. PubMed ID: 2849362 [No Abstract] [Full Text] [Related]
8. Successful treatment of metastatic glucagonoma with dacarbazine. Kurose T; Seino Y; Ishida H; Fujita J; Taminato T; Matsukura M; Imura H Lancet; 1984 Mar; 1(8377):621-2. PubMed ID: 6142319 [No Abstract] [Full Text] [Related]
9. Immunologic characterization of plasma glucagon components in a patient with malignant glucagonoma. Tanaka K; Watabe T; Shimizu N; Horiuchi T; Nakamura K; Yoshida H Metabolism; 1984 Aug; 33(8):728-33. PubMed ID: 6087085 [TBL] [Abstract][Full Text] [Related]
10. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature. Rosenbaum A; Flourie B; Chagnon S; Blery M; Modigliani R Digestion; 1989; 42(2):116-20. PubMed ID: 2548911 [TBL] [Abstract][Full Text] [Related]
16. The glucagonoma syndrome. Sonksen PH; Bloom SR J R Soc Med; 1990 Feb; 83(2):127. PubMed ID: 1969482 [No Abstract] [Full Text] [Related]
17. The glucagonoma syndrome and its management. Kessinger A; Lemon HM; Foley JF J Surg Oncol; 1977; 9(5):419-24. PubMed ID: 201809 [TBL] [Abstract][Full Text] [Related]
18. Retrobulbar neuritis as the first sign of the glucagonoma syndrome. Lambrecht ER; van der Loos TL; van der Eerden AH Int Ophthalmol; 1987 Oct; 11(1):13-5. PubMed ID: 2826358 [TBL] [Abstract][Full Text] [Related]
19. DTIC therapy in patients with malignant intra-abdominal neuroendocrine tumors. Altimari AF; Badrinath K; Reisel HJ; Prinz RA Surgery; 1987 Dec; 102(6):1009-17. PubMed ID: 2825370 [TBL] [Abstract][Full Text] [Related]
20. Glucagonoma syndrome. Report of two cases and literature review. Binnick AN; Spencer SK; Dennison WL; Horton ES Arch Dermatol; 1977 Jun; 113(6):749-54. PubMed ID: 194536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]